HK1097179A1 - Agents for treatment of glaucomatous retinopathy and optic neuropathy - Google Patents
Agents for treatment of glaucomatous retinopathy and optic neuropathyInfo
- Publication number
- HK1097179A1 HK1097179A1 HK07102203A HK07102203A HK1097179A1 HK 1097179 A1 HK1097179 A1 HK 1097179A1 HK 07102203 A HK07102203 A HK 07102203A HK 07102203 A HK07102203 A HK 07102203A HK 1097179 A1 HK1097179 A1 HK 1097179A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- agents
- optic neuropathy
- nrf2
- metabolites
- glaucomatous retinopathy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Otolaryngology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Saccharide Compounds (AREA)
- Quinoline Compounds (AREA)
- Pyrane Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US53177003P | 2003-12-22 | 2003-12-22 | |
PCT/US2004/042687 WO2005063295A1 (en) | 2003-12-22 | 2004-12-17 | Agents for treatment of glaucomatous retinopathy and optic neuropathy |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1097179A1 true HK1097179A1 (en) | 2007-06-22 |
Family
ID=34738696
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK07102203A HK1097179A1 (en) | 2003-12-22 | 2007-02-27 | Agents for treatment of glaucomatous retinopathy and optic neuropathy |
HK07114366.0A HK1110772A1 (en) | 2003-12-22 | 2007-12-31 | Agents for treatment of glaucomatours retinopathy and optic neuropathy |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK07114366.0A HK1110772A1 (en) | 2003-12-22 | 2007-12-31 | Agents for treatment of glaucomatours retinopathy and optic neuropathy |
Country Status (20)
Country | Link |
---|---|
US (2) | US20050137146A1 (de) |
EP (2) | EP1696958B1 (de) |
JP (2) | JP4755599B2 (de) |
KR (1) | KR20060127043A (de) |
CN (1) | CN1897972A (de) |
AT (2) | ATE357932T1 (de) |
AU (1) | AU2004308919B2 (de) |
BR (1) | BRPI0417987A (de) |
CA (1) | CA2547852A1 (de) |
CY (2) | CY1106623T1 (de) |
DE (1) | DE602004005617T2 (de) |
DK (2) | DK1803468T3 (de) |
ES (2) | ES2282926T3 (de) |
HK (2) | HK1097179A1 (de) |
MX (1) | MXPA06006980A (de) |
PL (2) | PL1803468T3 (de) |
PT (2) | PT1696958E (de) |
SI (2) | SI1803468T1 (de) |
WO (1) | WO2005063295A1 (de) |
ZA (1) | ZA200604862B (de) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6881198B2 (en) * | 2001-01-09 | 2005-04-19 | J. David Brown | Glaucoma treatment device and method |
BRPI0417987A (pt) * | 2003-12-22 | 2007-04-27 | Alcon Inc | agentes para o tratamento de retinopatia glaucomatosa e de neuropatia óptica |
WO2005102345A1 (en) * | 2004-03-30 | 2005-11-03 | Alcon, Inc. | Use of rho kinase inhibitors in the treatment of hearing loss, tinnitus and improving body balance |
JPWO2006030907A1 (ja) * | 2004-09-16 | 2008-05-15 | レドックス・バイオサイエンス株式会社 | 網膜保護剤 |
JP2009508584A (ja) * | 2005-09-16 | 2009-03-05 | ビージー インプラント インコーポレイテッド | 緑内障治療装置および方法 |
WO2008016095A1 (fr) * | 2006-08-02 | 2008-02-07 | Santen Pharmaceutical Co., Ltd. | REMÈDE PRÉVENTIF OU CURATIF POUR LES KÉRATOCONJONCTIVITES CONTENANT UN ACTIVATEUR DE Nrf2 EN TANT QUE MATIÈRE ACTIVE |
WO2008108825A2 (en) * | 2006-10-10 | 2008-09-12 | Burnham Institute For Medical Research | Neuroprotective compositions and methods |
JP2008247898A (ja) * | 2007-03-08 | 2008-10-16 | Santen Pharmaceut Co Ltd | トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤 |
CA2721665C (en) | 2008-04-18 | 2017-01-24 | Reata Pharmaceuticals, Inc. | Compounds including an anti-inflammatory pharmacore and methods of use |
CN102083442B (zh) | 2008-04-18 | 2014-08-13 | 里亚塔医药公司 | 抗氧化剂炎症调节剂:在c-17具有氨基和其它修饰的齐墩果酸衍生物 |
US7943778B2 (en) | 2008-04-18 | 2011-05-17 | Reata Pharmaceuticals, Inc. | Antioxidant inflammation modulators: C-17 homologated oleanolic acid derivatives |
SG10201808661XA (en) | 2010-04-12 | 2018-11-29 | Reata Pharmaceuticals Inc | Method of treating obesity using antioxidant inflammation modulators |
RU2472475C2 (ru) * | 2010-04-20 | 2013-01-20 | Учреждение образования "Белорусский государственный медицинский университет" (УО БГМУ) | Способ комбинированного лечения глаукомной оптической нейропатии |
US20130288985A1 (en) * | 2010-07-15 | 2013-10-31 | The Schepens Eye Research Institute Inc. | Compositions and methods of treatment of corneal endothelium disorders |
RU2447864C1 (ru) * | 2010-09-15 | 2012-04-20 | Инна Витальевна Щербинина | Способ лечения заболеваний зрительного нерва и сетчатки |
CA2840003A1 (en) | 2011-06-21 | 2012-12-27 | Ahmet Hoke | Compounds for treating peripheral neuropathies and other neurodegenerative disorders |
RU2546019C2 (ru) * | 2013-03-02 | 2015-04-10 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Воронежская государственная медицинская академия им. Н.Н. Бурденко" Министерства здравоохранения Российской Федерации | Способ лечения глаукомной оптической нейропатии |
WO2014179568A2 (en) | 2013-05-02 | 2014-11-06 | Odin Biotech | Two-layer ocular implant |
EP3240510A4 (de) | 2014-12-31 | 2018-09-19 | Microoptx Inc. | Verfahren und vorrichtungen zur behandlung von glaukom |
US10980667B2 (en) | 2015-09-30 | 2021-04-20 | Microoptx Inc. | Eye treatment devices and methods |
BR112019004639A2 (pt) | 2016-09-12 | 2019-07-16 | St Ip Holding Ag | formulações de 4-metil-5-(pirazin-2-il)-3h-1,2-ditiol-3-tiona, formulações de gosto modificado e métodos para produzir e usar as mesmas |
JP2019531344A (ja) | 2016-09-12 | 2019-10-31 | エスティー アイピー ホールディング エージー | 4−メチル−5−(ピラジン−2−イル)−3h−1,2−ジチオール−3−チオンの処方物、ならびにそれらの製造方法及び使用方法 |
NZ753546A (en) | 2016-11-08 | 2022-10-28 | Reata Pharmaceuticals Holdings Llc | Methods of treating alport syndrome using bardoxolone methyl or analogs thereof |
RU2647324C1 (ru) * | 2017-04-24 | 2018-03-15 | Игорь Евгеньевич Хаценко | Способ определения показаний для лечения амблиопии с помощью нейропептидного препарата |
MX2022012209A (es) * | 2020-03-30 | 2022-10-27 | Wuhan Neurophth Biotechnology Ltd Company | Vector de expresion del factor 2 relacionado con el factor nuclear humano e2 y aplicacion del vector de expresion. |
US11135220B1 (en) | 2020-04-08 | 2021-10-05 | St Ip Holding Ag | Methods of treating viral infections with formulated compositions comprising 4-methyl-5-(pyrazin-2-yl)-3H-1,2-dithiole-3-thione |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4456757A (en) * | 1981-03-20 | 1984-06-26 | Asahi Kasei Kogyo Kabushiki Kaisha | Isoquinolinesulfonyl derivatives and process for the preparation thereof |
US4678783B1 (en) * | 1983-11-04 | 1995-04-04 | Asahi Chemical Ind | Substituted isoquinolinesulfonyl compounds |
US4959389A (en) * | 1987-10-19 | 1990-09-25 | Speiser Peter P | Pharmaceutical preparation for the treatment of psoriatic arthritis |
US5124154A (en) * | 1990-06-12 | 1992-06-23 | Insite Vision Incorporated | Aminosteroids for ophthalmic use |
US5571523A (en) * | 1995-03-09 | 1996-11-05 | President And Fellows Of Harvard College | Antioxidant-induced apoptosis in vascular smooth muscle cells |
AU689036B2 (en) * | 1995-05-10 | 1998-03-19 | Kureha Chemical Industry Co., Ltd. | Pharmaceutical composition containing substance inhibiting HSP47 production |
JP3193301B2 (ja) * | 1995-09-14 | 2001-07-30 | 麒麟麦酒株式会社 | 生理活性タンパク質p160 |
US5906819A (en) * | 1995-11-20 | 1999-05-25 | Kirin Beer Kabushiki Kaisha | Rho target protein Rho-kinase |
US5681854A (en) * | 1995-11-22 | 1997-10-28 | Alcon Laboratories, Inc. | Use of aliphatic carboxylic acid derivatives in ophthalmic disorders |
DE69634414T2 (de) * | 1995-12-21 | 2005-11-17 | Alcon Laboratories, Inc., Fort Worth | Verwendung von substituierten isochinolinsulfonyl-verbindungen zur herstellung eines medikaments für die behandlung von glaukom und okularer ischämie |
DE69724108T2 (de) * | 1996-02-02 | 2004-06-09 | D.Western Therapeutics Institute, Nagoya | Isochinolinderivate und arzneimittel |
US6586425B2 (en) * | 1996-02-21 | 2003-07-01 | Wisconsin Alumni Research Foundation | Cytoskeletal active agents for glaucoma therapy |
JP3872834B2 (ja) * | 1996-03-04 | 2007-01-24 | 第一製薬株式会社 | メイラード反応抑制剤 |
AU738620B2 (en) * | 1996-08-12 | 2001-09-20 | Mitsubishi Pharma Corporation | Pharmaceutical agent containing Rho kinase inhibitor |
US5759787A (en) * | 1996-08-26 | 1998-06-02 | Tularik Inc. | Kinase assay |
KR100543151B1 (ko) * | 1997-01-16 | 2006-01-20 | 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 | 산화방지제와의 상승적인 상호작용을 통해 폴리시클릭 페놀계화합물의 세포 보호 효과를 증강시키는 조성물 |
US6573044B1 (en) * | 1997-08-07 | 2003-06-03 | The Regents Of The University Of California | Methods of using chemical libraries to search for new kinase inhibitors |
US6441033B1 (en) * | 1997-12-22 | 2002-08-27 | Alcon Manufacturing, Ltd. | 11β-fluoro 15β-hydroxy PGF2α analogs as FP receptor antagonists |
US6274338B1 (en) * | 1998-02-24 | 2001-08-14 | President And Fellows Of Harvard College | Human c-Maf compositions and methods of use thereof |
AU2440599A (en) * | 1998-02-25 | 1999-09-15 | Shionogi & Co., Ltd. | Therapeutic agent for complication of diabetes |
US20010041174A1 (en) * | 1998-11-24 | 2001-11-15 | Najam Sharif | Use of implanted encapsulated cells expressing glutamate transporter proteins for the treatment of neurodegenerative diseases |
US6020383A (en) * | 1999-01-11 | 2000-02-01 | Eastman Chemicals Company | Method for reducing blood cholesterol and/or blood triglycerides |
US6103756A (en) * | 1999-08-11 | 2000-08-15 | Vitacost Inc. | Ocular orally ingested composition for prevention and treatment of individuals |
US6573299B1 (en) * | 1999-09-20 | 2003-06-03 | Advanced Medical Instruments | Method and compositions for treatment of the aging eye |
US6812248B2 (en) * | 2000-07-05 | 2004-11-02 | John Hopkins University School Of Medicine | Prevention and treatment of degenerative diseases by glutathione and phase II detoxification enzymes |
GB0030727D0 (en) * | 2000-12-15 | 2001-01-31 | Lumitech Uk Ltd | Methods and kits for detecting kinase activity |
US6756063B2 (en) * | 2001-03-29 | 2004-06-29 | Zoltan Laboratories, Llc | Methods and compositions for the treatment of human and animal cancers |
CA2357265C (en) * | 2001-04-24 | 2004-04-13 | University Of British Columbia | Improved additive for livestock feeds |
US6884816B2 (en) * | 2001-08-31 | 2005-04-26 | Alcon, Inc. | Hydroxy substituted fused naphthyl-azoles and fused indeno-azoles and their use for the treatment of glaucoma |
TW201041580A (en) * | 2001-09-27 | 2010-12-01 | Alcon Inc | Inhibitors of glycogen synthase kinase-3 (GSK-3) for treating glaucoma |
US7199122B2 (en) * | 2001-10-02 | 2007-04-03 | Fox Chase Cancer Center | Methods for inhibiting angiogenesis |
AU2002357311A1 (en) * | 2001-12-18 | 2003-06-30 | Johns Hopkins University School Of Medicine | Prevention and treatment of oxidative stress disorders by glutathione and phase ii detoxification enzymes |
JP2005526719A (ja) * | 2002-02-15 | 2005-09-08 | ディーエスエム アイピー アセッツ ビー.ブイ. | 血管新生関連病状の治療および予防のための、リコペンを含む組成物 |
US20030219846A1 (en) * | 2002-02-28 | 2003-11-27 | Pfizer Inc. | Assay for activity of the ActRIIB kinase |
TW200407119A (en) * | 2002-08-05 | 2004-05-16 | Kin-Ping Wong | Methods and compositions to treat conditions associated with neovascularization |
US6747025B1 (en) * | 2002-11-27 | 2004-06-08 | Allergan, Inc. | Kinase inhibitors for the treatment of disease |
US20050137147A1 (en) * | 2003-12-22 | 2005-06-23 | Alcon, Inc. | Agents for treatment of diabetic retinopathy and drusen formation in macular degeneration |
TW200526224A (en) * | 2003-12-22 | 2005-08-16 | Alcon Inc | Short form c-Maf transcription factor antagonists for treatment of glaucoma |
BRPI0417987A (pt) * | 2003-12-22 | 2007-04-27 | Alcon Inc | agentes para o tratamento de retinopatia glaucomatosa e de neuropatia óptica |
-
2004
- 2004-12-17 BR BRPI0417987-0A patent/BRPI0417987A/pt not_active IP Right Cessation
- 2004-12-17 PT PT04814825T patent/PT1696958E/pt unknown
- 2004-12-17 PT PT07105047T patent/PT1803468E/pt unknown
- 2004-12-17 DE DE602004005617T patent/DE602004005617T2/de active Active
- 2004-12-17 EP EP04814825A patent/EP1696958B1/de not_active Not-in-force
- 2004-12-17 DK DK07105047.0T patent/DK1803468T3/da active
- 2004-12-17 PL PL07105047T patent/PL1803468T3/pl unknown
- 2004-12-17 ES ES04814825T patent/ES2282926T3/es active Active
- 2004-12-17 CA CA002547852A patent/CA2547852A1/en not_active Abandoned
- 2004-12-17 AU AU2004308919A patent/AU2004308919B2/en not_active Ceased
- 2004-12-17 ZA ZA200604862A patent/ZA200604862B/en unknown
- 2004-12-17 AT AT04814825T patent/ATE357932T1/de active
- 2004-12-17 WO PCT/US2004/042687 patent/WO2005063295A1/en active IP Right Grant
- 2004-12-17 KR KR1020067014097A patent/KR20060127043A/ko not_active Application Discontinuation
- 2004-12-17 JP JP2006545535A patent/JP4755599B2/ja not_active Expired - Fee Related
- 2004-12-17 AT AT07105047T patent/ATE523208T1/de active
- 2004-12-17 MX MXPA06006980A patent/MXPA06006980A/es active IP Right Grant
- 2004-12-17 EP EP07105047A patent/EP1803468B1/de not_active Not-in-force
- 2004-12-17 ES ES07105047T patent/ES2371364T3/es active Active
- 2004-12-17 DK DK04814825T patent/DK1696958T3/da active
- 2004-12-17 PL PL04814825T patent/PL1696958T3/pl unknown
- 2004-12-17 SI SI200431767T patent/SI1803468T1/sl unknown
- 2004-12-17 SI SI200430296T patent/SI1696958T1/sl unknown
- 2004-12-17 US US11/015,888 patent/US20050137146A1/en not_active Abandoned
- 2004-12-17 CN CNA2004800384580A patent/CN1897972A/zh active Pending
-
2007
- 2007-02-27 HK HK07102203A patent/HK1097179A1/xx not_active IP Right Cessation
- 2007-05-25 CY CY20071100711T patent/CY1106623T1/el unknown
- 2007-12-31 HK HK07114366.0A patent/HK1110772A1/xx not_active IP Right Cessation
-
2010
- 2010-11-04 JP JP2010247809A patent/JP2011046736A/ja not_active Withdrawn
-
2011
- 2011-02-22 US US13/031,742 patent/US20110144127A1/en not_active Abandoned
- 2011-11-24 CY CY20111101143T patent/CY1112393T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1097179A1 (en) | Agents for treatment of glaucomatous retinopathy and optic neuropathy | |
PT762837E (pt) | Processo para melhorar a durabilidade e/ou estabilizacao de produtos degradaveis microbiologicamente | |
HK1097828A1 (en) | 42-0-alkoxyalkyl rapamycin derivatives and compositions comprising same | |
DK1572127T3 (da) | Enzymbehandling af fødevarer til cøliaki | |
NO20034094L (no) | Sammensetninger som omfatter et antidiar±middel og et epotilon eller et epotilonderivat | |
EP1719410A4 (de) | Verfahren zur bekämpfung von pflanzenkrankheitsschäden durch verwendung von bacillus und eines bekämpfungsmittels | |
BR0014214A (pt) | Imidazoquinolinas substituìdas com amida | |
BRPI0417996A (pt) | agentes para tratamento de retinopatia diabética e formação de gánglios em degeneração macular | |
NO20033664L (no) | Mikroorganisme for biologisk detoksifisering av mykotoksiner, dvs okratoksiner og/eller zearleoner, så vel som fremgangsmåte og anvendelsederav | |
EP0858996A4 (de) | Mittel zum schutz von nervenzellen | |
NO20052359D0 (no) | Karbostyilderivater og serotonin reopptaks inhibitorer for behandling av humor forsyrrelser | |
BR0314419A (pt) | Compostos de 5-croman-5-il-etilamina substituìdos, seu uso e composição farmacêutica incluindo-o | |
BR0316775A (pt) | Novos análogos de benzopirano e seu uso para o tratamento de glaucoma | |
ES2036238T3 (es) | Derivados de hidroxietil-azolilo. | |
ES2126795T3 (es) | Formulacion y procedimiento de control de los nematodos parasitos de las plantas. | |
ES2159622T3 (es) | Derivado del diazacicloalcanoalquilsulfonamida. | |
ATE526992T1 (de) | Methode zum schutz therapeutischer zusammensetzungen von hostvermittelter inaktivierung | |
AR034508A1 (es) | Agente protector de las neuronas retinales. | |
GT200000136A (es) | Gen de streptomyces avermitilis que dirige la relacion de avermectinas b2 : b1 (2). | |
ES2062570T3 (es) | L-alfa-glicerofosforil-d-mio-inositol para el tratamiento de neuropatias perifericas y de cerebropatias. | |
ES2163988A1 (es) | Proteina con actividad antifungica. | |
BR0215752A (pt) | Piranoindazóis e seu uso no tratamento de glaucoma | |
ES2093054T3 (es) | Antibioticos ab-023 y procedimiento para su preparacion. | |
GT200300260A (es) | Derivados de anilinopirazol utiles en el tratamiento de la diabetes | |
ECSP993087A (es) | Uso de derivados de tiazolidinediona para el tratamiento o prevencion de cataratas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20171217 |